Roche says it will appeal against NICE no for Tarceva
This article was originally published in Scrip
Executive Summary
Roche says it is going to appeal against draft guidance from NICE, the health technology appraisal institute for England and Wales, which turns down the company's Tarceva (erlotinib) as a maintenance treatment for some NHS patients with advanced non-small cell lung cancer (NSCLC). The institute said it had too many doubts about the clinical-effectiveness of the drug in this setting.